Its also why patients must become their own advocate and participate in the process of managing their symptoms
3,4 American Association of Clinical Endocrinology guidelines recommend treatment with GLP-1RA in T2DM patients with coexisting ASCVD, high-risk for ASCVD, heart failure, or chronic kidney disease regardless of their glycemic control due to their organ protective effects
Piccirillo F, Mastroberardino S, Nusca A, Frau L, Guarino L, Napoli N et al
Future research must prioritize definitive comparative cardiovascular outcome trials and rigorous real-world analyses to address current observational limitations and fully elucidate long-term comparative effectiveness
Possible side effects Like all products, this product can cause side effects, although not everybody gets them
Cannot redeclare control with same name "grid_3_qv_typography_font_weight"